AI in market research is meaningless unless it changes commercial outcomes
AI only matters in market research when it improves decisions, shapes investment, and increases the odds of market success.
Watch our latest webinar: Who can you trust? A pharma leader’s guide to vetting AI for insights
View NowOur Thinking
AI only matters in market research when it improves decisions, shapes investment, and increases the odds of market success.
Most insight leaders can now see the strategic potential of AI. They understand where it could help them with faster sense-making, broader exploration, and decisions made with greater confidence when time is short.
Pharma doesn’t have an insight problem – it has an operating model problem. Despite unprecedented investment in data, research and content development, outcomes continue to disappoint. 77% of pharma content never reaches its intended audience. Half of launches miss expectations, and one in four delivers less than half its forecast.
Imagine you lead professional marketing for a GLP-1 for weight management. Your year is mapped against carefully scheduled campaigns.
In late July, Day One Strategy hosted a webinar that brought together over 100 pharmaceutical insights leads to discuss a topic at the cutting edge of market research: synthetic data and respondents. This article summarises the key takeaways from this engaging discussion, offering a window into how industry leaders are thinking about the future of data-driven insights in pharma.